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Several lines of evidence indicate that the immune system, inflammation, and coagulation
are simultaneously activated in autoimmune and immune-mediated skin diseases.
Pro-inflammatory cytokines such as interleukin-6 and tumor necrosis factor-alpha induce
the expression of the main initiator of coagulation, i.e., tissue factor. The proteases
of coagulation in turn act on protease-activated receptors inducing the expression
of various pro-inflammatory cytokines triggering inflammation. The cross-talk among
immune system, inflammation, and coagulation amplifies and maintains the activation of
all three pathways. This review focuses on three skin disorders as chronic spontaneous
urticaria (CSU), angioedema, and bullous pemphigoid (BP), in which the relationships
among the three systems have been investigated or their clinical consequences are
relevant. Markers of thrombin generation, fibrinolysis, and inflammation have been
reported to be increased in the plasma during flares of CSU and angioedema, as well as
in the active phase of BP, with the marker levels reverting to normal during remission. The
coagulation activation seems to be important only at local level in CSU and angioedema
while both at local and systemic levels in BPwhich is the only condition associated with an
increased thrombotic risk. The prothrombotic state in autoimmune skin diseases raises
the question of the indication of anticoagulant treatment, particularly in the presence of
other cardiovascular risk factors.
Keywords: coagulation, autoimmunity, urticaria, angioedema, bullous pemphigoid, psoriasis, atopic dermatitis,
dermatitis herpetiformis
INTRODUCTION
Immune system, blood coagulation and inflammation strictly interact in providing a defense
against a variety of potentially injurious stimuli, such as infections and tissue damages (1). The
molecular mechanisms of this interaction have been largely elucidated. Indeed, pro-inflammatory
cytokines, like interleukin 1 (IL-1), IL-6, and tumor necrosis factor alpha (TNF-α), induce the
expression of tissue factor (TF) the main initiator of blood coagulation whereas downregulate the
natural anticoagulants such as antithrombin, protein C, and TF pathway inhibitor (2). On the other
hand, the coagulant mediators (FVIIa, FXa, and FIIa) in turn act on protease-activated receptors
(PAR) inducing the expression of pro-inflammatory cytokines (3, 4). The relationships between the
activation or dysfunction of the immune system and the coagulation system are evident in systemic
autoimmune or immune-mediated diseases including lupus erythematosus (5, 6), rheumatoid
arthritis (7, 8), and inflammatory bowel diseases (9, 10) which show an increased risk of thrombosis.
A few studies suggested the involvement of blood coagulation also in some immune-mediated skin
disorders whose aspects will be analyzed in the present review.
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Immune-mediated inflammatory skin diseases comprise a
group of heterogeneous chronic disorders that share similar
immune-mediated pathogenic mechanisms as well as genetic
susceptibility. Although their specific etiologies remain often
unknown, all are recognized to involve dysregulation of
the immune system, including an over-expression of the
pro-inflammatory cytokines. In autoimmune and immune-
mediated skin disorders, the cross-talk between inflammation
and coagulation creates a self-refueling loop which amplifies and
sustains the activation of both systems (3). Growing evidence
suggests that this has both local and systemic implications.
The aim of the present study is to focus on several skin
disorders in which the relationships between immune response,
inflammation and blood coagulation have been investigated
and/or their clinical consequences are relevant such as chronic
spontaneous urticaria, angioedema, and bullous pemphigoid.
CHRONIC SPONTANEOUS URTICARIA
Urticaria is a common skin disease characterized by short-lived
swellings, called wheals, which resolve in <24 h. Urticaria can
be classified according to duration and etiology as acute or
chronic (11). Chronic urticaria is defined as urticaria with or
without angioedema lastingmore than 6weeks and can be further
classified according to whether it is inducible or not into chronic
inducible urticaria or chronic spontaneous urticaria (CSU).
Despite the great research effort of the last 20 years, etiology
and pathogenesis of CSU remain largely unclear. However, there
is growing evidence that different biologic systems including
autoimmunity (12–14), inflammation (15–18), coagulation (19),
and auto-allergy (20–23) are involved in the mechanisms leading
to mast cell and basophil degranulation and hence to wheal
formation (Figure 1).
The autoimmune mechanism is based on the presence
of circulating histamine-releasing IgG autoantibodies directed
against either the high-affinity IgE receptor (FcεRI) on both mast
cells and basophils (in most cases) or membrane-bound IgE (in a
minority of patients) (12, 13, 24). In a variable proportion (30–
60%) of patients with active disease, the intradermal injection
of autologous serum (autologous serum skin test, ASST) causes
a wheal-and-flare reaction (19). This phenomenon mirrors
the activation of mast cells and basophils as well as of the
complement cascade by these autoantibodies. Experimental
and clinical findings have supported an autoimmune origin
in about 30–50% of patients affected with CSU (12, 13).
Also other autoantibodies are involved in CSU pathogenesis
such as autoantibodies to CD23, the low-affinity IgE receptor
(FcεRII), which contribute to eosinophil activation and mast cell
degranulation (14, 25). The possible autoimmune nature of CSU
is further supported by the association with other autoimmune
diseases, notably thyroiditis, and the increased frequency of HLA
DRB1∗04 (DR4) (26).
Inflammation is involved in the pathophysiology CSU,
as demonstrated by the increase in different markers of
inflammation, such as matrix metalloproteinase, serum C-
reactive protein, IL-6, IL-6 soluble receptor, eosinophil cationic
protein (ECP), TNF-α, complement, and others, which are
related to CU activity (15–17, 27). On the contrary, adipokines
that affect immune responses and exert an anti-inflammatory
effect, such as lipocalin 2, have a negative association with CU
activity (18).
Coagulation involvement in the pathogenesis of CSU is
supported by many lines of evidence (28–33). The original
observation that the autologous plasma skin test (APST)
may score positive in some ASST-negative patients (29) has
given rise to investigation of the coagulation system in CSU
patients. In a study that dates back over 10 years, some of
us found that CSU patients have elevated plasma levels of
prothrombin fragment F1+2, suggesting thrombin generation
(29). In subsequent studies, we found that CSU patients show an
activation of the tissue factor pathway of coagulation cascade by
activated eosinophils (30). Immunohistochemical experiments
showed tissue factor expression by eosinophils present in the
inflammatory infiltrate of CSU skin lesions (31). These data
highlight the relevance of eosinophils in CSU as a source of
tissue factor, in accordance with studies showing that eosinophils
store tissue factor and transfer it to their cell membrane
during activation (34). Eosinophils may be activated directly by
autoantibodies directed against the FcεRII CD23 antigen (14)
or secondarily to the activation of mast cells by anti-FcεRI
and anti-IgE autoantibodies (24). The activation of the tissue
factor pathway of coagulation results, in turn, in the generation
of thrombin which, in experimental models, has been shown
to induce edema through an increase in vascular permeability
directly by acting on endothelial cells (35) and indirectly by
generating C5a (36, 37), by triggering mast cell degranulation
(38–41) and by releasing inflammatory mediators (42, 43). Pro-
inflammatory cytokines, such as IL-6 and TNF-α, induce the
expression of tissue factor (3, 44), sealing the mutual activation
of the two systems, i.e., coagulation and inflammation. The
complexes between tissue factor, activated factor VII (FVIIa) and
FVa+FXa also activate mast cells via PAR-2, thus amplifying the
activation of these cells in CSU (40). On the other hand, mast
cell-derived tryptase can induce thrombin generation through
a direct activation of prothrombin (45), thus constituting an
amplification loop. It must be taken into account also an opposite
effect of mast cells on inflammatory response. In fact, recent
studies showed that mast cells can also limit thrombin-induced
immediate skin inflammatory responses by releasing substances
able to reduce the activity of thrombin, for example proteases, like
mast cell protease 4 (MCPT4) (46). During severe exacerbations
of the disease, CSU patients show marked increase of plasmatic
markers of thrombin generation, like prothrombin fragment F1
+ 2, FVIIa and thrombin-antithrombin complex (47–49), as well
as of fibrinolysis (24, 31, 50). The increase of D-dimer, marker of
fibrinolysis, is associated with disease severity (24) and its level
resulted higher when compared with that of patients affected
with psoriasis (51). Interestingly, a study detected the increase
of D-dimer and fibrinogen/fibrin degradation products (FDP),
produced by fibrinolysis of either stabilized or non-stabilized
fibrin, in patients with CSU, but not in healthy individuals
or in patients with inducible type of urticaria (52). Finding
that the increase in plasma markers of thrombin generation
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FIGURE 1 | Mechanisms of eosinophil and mast cell activation in chronic spontaneous urticaria. Mast cells release histamine and other effector molecules after
stimulation by autoantibodies directed against the high-affinity IgE receptor (FcεRI) and IgE, complement anaphylatoxin C5a, eosinophil-derived major basic protein
(MBP), thrombin, and IgE-autoallergen complexes. The most important autoallergens are: interleukin-24 (IL-24), double stranded DNA (dsDNA), thyroperoxidase
(TPO), tissue factor. Eosinophils are activated by autoantibodies directed against the low-affinity IgE receptor (FcεRII) and potentially by other factors. Upon their
activation, eosinophils release MBP, and express tissue factor which in turn activates the coagulation cascade (factors VII, X, VIII, V, and prothrombin) leading to
thrombin generation. Thrombin induces mast cell degranulation as well as increased vascular permeability. Thrombin generation is demonstrated by the presence of
fragment F1+2 released from prothrombin after its activation. Finally, fibrin degradation is documented by elevated plasma levels of the fibrin fragment D-dimer during
the active phase of the disease.
and fibrinolysis parallels plasma C-reactive protein (CRP) levels
further remarks the close link between coagulation activation and
inflammation in CSU pathogenesis (53). The interplay between
inflammatory and coagulation/fibrinolysis factors in CSU may
lead tomaintenance and amplification of urticarial inflammation.
Both the activation of coagulation and fibrinolysis decrease till
complete normalization during remission and biomarker levels
return to normal values (31, 49, 54, 55). A limited number of
studies investigated the role of platelets in CSU, with no univocal
data (56). Platelet activation was found to occur in some skin
inflammatory disorders, such as atopic dermatitis and psoriasis
(57, 58). Based on these findings, platelets are regarded as a
possible link between chronic inflammatory and pro-coagulant
states (59). It may be hypothesized that platelet activation may
be one of the triggering factors of the coagulation cascade
in CSU too, leading to the activation of histamine-releasing
effector cells. However, current evidence indicates that the simple
determination of platelet indices is not reliable and lacks useful
implications in the clinical practice (56).
The activation of the coagulation cascade in CSU pathogenesis
may have clinical effects not only in eliciting skin lesions,
namely wheal eruption, but also at systemic level. The most
important potential clinical consequence of the hypercoagulable
state in CSU patients is an increased thrombotic risk (25). In
spite of this, patients with CSU are not reported to have an
increased risk for thrombotic events. A possible explanation is
that the activation of coagulation occurs mostly extravascularly
and can be efficiently counteracted by coagulation inhibitors
and fibrinolysis. Other potential clinical implications of the
recognized involvement of coagulation in the pathogenesis of
CSU are the possible therapeutic efficacy of pharmacological
agents that interfere with the coagulation pathway. A few reports
indicate that heparin, an anticoagulant which potentiates the
effect of antithrombin, may be effective in treating CSU (60, 61).
An anticoagulant/anti-fibrinolytic therapy, namely nadroparin
and tranexamic acid, has been found effective in some patients
with refractory CSU and elevated D-dimer levels (62). Moreover,
warfarin, an oral anti-vitamin K drug, induced a good response
in patients with CU unresponsive to antihistamines in a
double-blind, placebo controlled study (63). With reference to
further clinical implications of the activation of coagulation and
fibrinolysis, elevated D-dimer plasma level has been found to
be associated both with a poor response to antihistamines (64)
and with a limited response to cyclosporine treatment (65). It
is worthy of note that D-dimer plasma levels were observed to
parallel the clinical response to omalizumab treatment, dropping
in responders and remaining unchanged in non-responders
(20, 66). Furthermore, elevated D-dimer plasma levels seem to
be a predictive marker of prompt and complete response to
the anti-IgE monoclonal antibody (67). It may be assumed that
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in a subset of CSU patients, the activation of the coagulation
cascade has a key role in the pathogenesis of this disorder.
In a recent study, the treatment with omalizumab induced a
significant decrease in WBC count, platelet count, neutrophil
count, ratio of platelet to lymphocyte (PLR), ratio of neutrophil
to lymphocyte (NLR) and CRP level and a significant increase in
mean platelet volume (MPV) and eosinophil count (68). Taken
together, these data suggest that in CSU patients omalizumab
may be effective not only antagonizing IgE but also affecting
a number of other pathways (69). In particular, it can exert
inhibitory effects on inflammation and coagulation cascade,
further confirming the strict interaction between immunity,
inflammation, and coagulation.
The “autoallergic” mechanism, which has been recently
identified, is mediated by specific IgE to different allergens,
including double-strained DNA (21), thyroperoxidase (22), IL-24
(23), tissue factor, and thyroglobulin (20). IgE anti-autoallergens
seem to cause “autoallergic” mast cell degranulation. In
particular, the elevated specific IgE antibodies to tissue factor
have been demonstrated to be functionally able to mediate the
release of leukotriene C4 by tissue factor-stimulated peripheral
basophils (20). Tissue factor, the main initiator of coagulation,
is overexpressed in CSU lesional skin (32) where it can activate
coagulation and is also accessible to mast cell-bound IgE.
Thus, IgE anti-tissue factor could cause “autoallergic” mast
cell degranulation, linking the autoallergic and coagulation
activation pathways. The presence of autoreactive IgE against
several targets in patients with CSU might explain, at least in
part, the clinical success of the humanized monoclonal anti-IgE
antibody omalizumab.
ANGIOEDEMA
Angioedema refers to a circumscribed, non-itchy edema of
the subcutaneous tissues mostly involving lips, face, neck and
extremities and/or submucosal tissues affecting oral cavity,
larynx and gut (70). It typically lasts from many hours to 3
days before the tissue returns to normal. Angioedema is life-
threatening if it occurs in the upper airways and can be very
painful if it occurs in the gastrointestinal tract (70). Wheals
and angioedema often coexist but may also present alone (71).
Most of these conditions are mainly mediated by histamine and
other pro-inflammatory mediators released by mast cells and
basophils (72). Overall, angioedema can be caused by allergies,
inherited or acquired deficiencies of C1-inhibitor protein, or
drug reactions. In many cases its pathophysiology remains
undetermined (54). Among the vasoactive agents involved in
mediating swelling attacks in angioedema, histamine, released
by mast cells or basophils, has a prominent role, especially in
allergic reactions and in cases of associated urticaria (73). Anti-
histamines are effective agents in these forms. However, there
are some subtypes of angioedema that do not respond to anti-
histamine, such as angioedema due to C1-inhibitor deficiency,
angioedema due to ACE inhibitors and a rate of idiopathic
angioedema (54). Bradykinin is a recognized mediator of the
increased vascular permeability in angioedema. Bradykinin is
a vasoactive peptide acting on specific receptors such as B2
receptors that are constitutively present on the endothelium and
B1 receptors that are expressed during inflammatory reactions.
Bradykinin receptor signaling induces peripheral vasodilatation,
enhancement of vascular permeability and subsequent vascular
leakage. Bradykinin is the end-product of the contact activation
system. This enzymatic cascade circulates in the plasma and
consists of factor XII (FXII), plasma prekallikrein (PPK), and
high molecular weight kininogen (HK). This system is linked
to the intrinsic coagulation system via factor XI (FXI). Animal
models showed that production of bradykinin in plasma is
∼50% dependent on FXII (74). This suggests the presence
of alternative pathways generating bradykinin in vivo. The
endothelial cell-derived factors heat shock protein 90 (HSP90) and
prolylcarboxypeptidase may be involved in FXII-independent
release of bradykinin (75).
Bradykinin was first identified as a mediator for hereditary
angioedema (HAE) (76, 77). The genetic form of C1-inhibitor
deficiency is due to mutations in one of the two alleles of the
C1-inhibitor gene, which leads to either reduced plasma protein
levels [hereditary angioedema [HAE] type I] or normal levels but
reduced protein function (HAE type II) (78). HAE type III is
a rare subtype of HAE that is not connected with C1-inhibitor
deficiency but with a dysregulation of the contact (plasma
kallikrein-bradykinin) system (79). In a subset of patients with
HAE with normal C1-inhibitor, a gain-of-function mutation in
FXII has been identified (80). The acquired form of C1-inhibitor
deficiency is known as acquired angioedema and is due to C1-
inhibitor consumption associated with the presence of anti-C1-
inhibitor autoantibodies and/or lymphoproliferative disorders
(81). Bradykinin involvement in angioedema pathogenesis is not
limited to hereditary forms. Bradykinin is a key mediator in
patients with acquired C1-inhibitor deficiency due to underlying
auto-immune or lymphoproliferative diseases (82) as well as
in those treated with anti-hypertensive drugs that inhibit
bradykinin breakdown, such as angiotensin-converting enzyme
inhibitors (83). It is also possible that bradykinin may play
a supportive role in forms of angioedema that are currently
classified as “histaminergic” (84, 85). C1-inhibitor deficiency
involves different biological systems that interplay during
angioedema attacks. In fact, C1 inhibitor is a serine protease
inhibitor (serpin) that blocks the activity of (i) C1r and C1s
in the complement system, (ii) factor XII and kallikrein in the
contact system, (iii) factor XI and thrombin in the coagulation
system, and (iv) tissue plasminogen activator and plasmin in
the fibrinolytic system (86). A deficiency in C1 inhibitor results
in the hyperactivation of the contact system (87, 88), which
leads to the generation of bradykinin. Furthermore, C1-inhibitor
deficiencies activate the complement (89) as well as coagulation
(90, 91) and fibrinolysis systems (92, 93). Thus, the unregulated
activation of coagulation leads to the generation of thrombin,
which can potentiate the vasoactive effect of bradykinin both
directly (35, 94) and by releasing fibrinopeptides, which enhance
the effects of kinins (95). It may be argued that in angioedema
due to C1-inhibitor deficiency, thrombin acts synergistically
with other vasoactive substances released by the concomitant
activation of contact system, complement, or mast cells leading
in turn to increased vasopermeability. Plasmin has been assumed
to act as a main trigger for contact system activation and
bradykinin production in the pathogenesis of most forms of
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HAE and specific forms of non-hereditary angioedema (96, 97).
Indeed, several clinical observations supported the relevance of
plasmin as a natural FXII activator and evidence for plasmin-
dependent bradykinin generation as a cause of angioedema
during treatment with fibrinolytic agents is accumulating (73).
Consistent with this hypothesis, complexes of plasmin with its
inhibitor α2-antiplasmin are elevated during attacks of HAE
due to C1-inhibitor deficiency, as are the levels of markers of
ongoing fibrinolysis, like D-dimer (98). Similarly to CSU, in
patients with angioedema there is lack of prothrombotic features
(55, 99). Therefore, it may be assumed that in angioedema, factor
XII–driven contact system starts inflammatory mechanisms
via the bradykinin-producing kallikrein-kinin system, without
procoagulant effects (35). Alternatively, it has been proposed that
the extreme vascular leakage may move the plasma coagulation
factors into the extravascular space, triggering coagulation in
the absence of vascular injury or intravascular thrombi (73).
Therapy targeting the contact system has been successful in HAE,
strongly supporting that angioedema is mediated via bradykinin
production (73). Anti-fibrinolytic therapy, mainly tranexamic
acid, has been used as prophylactic therapy for HAE attacks for
some decades (100).
BULLOUS PEMPHIGOID
Bullous pemphigoid (BP) is an autoimmune blistering disease
that mainly affects the elderly and carries a high risk of death
(101, 102), mostly due to sepsis and cardiovascular events
(103). Either comorbidities or immunosuppressive treatments
seem to concur on BP mortality (104). Albeit rare, it is
the most common autoimmune blistering disease in Western
countries (105). It involves the skin and rarely the mucous
membranes and is characterized by the presence of tense blisters
usually surrounded by erythematous-edematous, urticaria-like
plaques (106, 107). BP has a chronic relapsing evolution,
with spontaneous exacerbations and remissions (108). The
pathophysiology of BP is linked to the presence of circulating
IgG autoantibodies directed against two antigens, BP180 and
BP230, which are components of junctional adhesion complexes
called hemidesmosomes that promote dermoepidermal cohesion
(109, 110) with the contributory role of other pathomechanisms
(Figure 2). BP180 (type XVII collagen) autoantibodies have
been demonstrated to be directly pathogenic by triggering
an inflammatory cascade. Inflammatory cells, particularly
autoreactive T cells and eosinophils, produce and release a
number of cytokines and soluble factors that amplify and
maintain tissue damage, which ultimately leads to subepidermal
blister formation (111). During acute phase of BP, autoreactive
T helper (Th) 1, Th2, and Th17 lymphocytes cooperatively
play a role in the development of the disease process (112–
114). Although the role of Th17 cells in human BP is not
completely defined, recent experimental data showed that IL17A-
deficient mice are protected against autoantibody-induced BP,
and pharmacological inhibition of lL-17A reduces the induction
of BP (115). Moreover, a dysfunction of both T and B
regulatory cells, whose immunosurveillance action is critical in
preventing autoimmunity, was observed in lesional skin of BP
patients (116, 117). The involvement of many cellular players
in the BP inflammatory process is supported by elevated serum
levels of activation markers, including molecules released by
T cells upon their stimulation, molecules involved in B-cell
maturation, granule proteins liberated from activated mast cells,
neutrophils and eosinophils and adhesion molecules indicative
of neutrophil and platelet activation. Complement activation
is considered to be critical for blister formation too. Indeed,
complement activation by autoantibodies ex vivo as measured by
the complement-fixation assay in serum was correlated with the
clinical disease activity in patients with BP (118). Experimental
data in murine models demonstrate that complement-dependent
and -independent mechanisms coexist in blister formation. On
the basis of knock out mice and pharmacological inhibition
studies, the activated 5th component of complement (C5a)
appears to be involved, and its receptor 1 (C5aR1) seems to
be important during the early phase of the disease while its
receptor 2 (C5aR2) seems to be protective. Once the skin
inflammation has fully developed, release of reactive oxygen
species and proteases from neutrophils and macrophages may
become independent of complement (119). Several studies
showed that the coagulation cascade is activated in BP and
correlates with the severity of the disease (25, 120–123). In
particular, coagulation activation markers have been found to be
increased at both local level, i.e., in blister fluid, and systemically,
i.e., in plasma (123). It has been hypothesized that the activation
of blood coagulation is induced by the inflammatory response
underlying BP pathogenesis. In this regard, eosinophils are
highly represented in the inflammatory infiltrate of the lesional
skin and their levels are often increased in peripheral blood
(123–125). Elevated concentrations of secretory granules, such
as eosinophil cationic protein (ECP) (126, 127) as well as
increased levels of IL5, the main cytokine involved in eosinophil
biology (128, 129), and IL16, a chemotactic factor for eosinophils
(130), in blister fluid and sera of patients with BP confirm
the involvement of eosinophils in the pathogenesis of this
disease. Eosinophils are recognized to concur in BP elicitation
by producing and releasing matrix metalloproteinase (MMP)-
9, which plays a key role in degrading BP180 and cleaving
the dermal-epidermal junction (131). Release of elastase and
gelatinase, namely 92 kDa gelatinase, may further contribute
to tissue damage and blister formation (132, 133). Eosinophil
degranulation was demonstrated not only in fully developed
blisters, but also at the earliest stages of blister development and
urticarial lesions of BP (134, 135). Moreover, eosinophils have
been postulated as potential intermediates between anti-BP180
IgE autoantibodies, whose pathogenic role in BP has increasingly
recognized in recent years, and dermo-epidermal junction
separation (136, 137). High-affinity IgE receptors (FcεRI) that are
highly expressed on eosinophils in BP patients could enhance
the capability of eosinophils to bind IgE and thus influence
their subsequent degranulation (138). In recent reports, the
monoclonal anti-IgE antibody omalizumab resulted effective in
treating patients affected with BP, despite ongoing high levels
of anti-skin IgG antibodies (139, 140). This provides further
evidence of an independent role for autoreactive IgE-mediated
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FIGURE 2 | Pathomechanisms of the blister formation in bullous pemphigoid including the involvement of coagulation activation. The dermo-epidermal detachment is
due to the interaction of autoantibodies with two hemidesmosomal antigens (BP180 and BP230), followed by complement activation and leukocyte infiltration.
Autoreactive T lymphocytes cooperate with B lymphocytes in the autoantibody production; in addition, they release cytokines, most notably IL-5 and IL-16, and other
soluble factors responsible for the recruitment and activation of eosinophils. In lesional skin, eosinophils produce and release metalloproteinases, elastase, and
gelatinase which contribute to tissue damage. Moreover, eosinophils strongly express tissue factor, which is the main initiator of the coagulation cascade (factors VII,
X, VIII, V, and prothrombin) leading to generation of thrombin. This last increases the permeability of blood vessels, amplifying the inflammatory network. Neutrophils
contribute in the pathogenesis of bullous pemphigoid by releasing reactive oxygen species (ROS) and proteases. Finally, complement is activated upon binding of the
pathogenic autoantibodies to their autoantigens.
inflammation in BP skin lesion development. Eosinophils are
also involved in itch induction, mainly due to the release of
IL-31 (141, 142). IL31 exerts a chief role in itch, by activating
endothelin-1 responsive neurons and by increasing the release
of brain natriuretic peptide (BNP), a central mediator of itch
(143, 144). With specific reference to the activation of the
coagulation cascade in BP, it correlates with eosinophilia other
than severity of the disease, thus indicating that eosinophils
play a pivotal role in this process (123). Immunohistochemistry
showed that eosinophils strongly express TF in lesional skin, as
confirmed also by co-localization studies (120, 123). Eosinophils
are a major intravascular location for TF storage and exposure.
On the other hand, TF facilitates the early transendothelial
migration of eosinophils (34). Consistent with these findings, it
may be supposed that extrinsic blood coagulation initiated via
TF expressed by eosinophils contributes to local inflammation
and blister formation (145). In fact, TF plays an important
role in the inflammatory process, in addition to its well-
documented prothrombotic properties (34). In BP patients,
increased skin expression of adhesins and MMPs has been
considered an effect of TF action (146). TF is a recognized
factor connecting the immune system with coagulation system.
Pro-inflammatory cytokines, such as TNF and IL-6, which
are increased in BP, induce TF expression (25), as found
also in other, very heterogeneous inflammatory conditions
(147–149). Activation of the extrinsic coagulation pathway
generates thrombin that increases the permeability of blood
vessels (150, 151). The presence of thrombin may play a
direct role in the pathogenesis of BP by increasing vascular
permeability, thus favoring the transendothelial migration of
inflammatory cells and their accumulation in the skin. Activated
proteases, in turn, act on PARs and induce the expression of
various pro-inflammatory cytokines, and this cross-talk between
inflammation and coagulation amplifies and maintains the
activation of both systems (123). It is noteworthy that BP patients
have high levels of coagulation activation markers, such as
prothrombin fragment F1+2 (indicating thrombin generation)
and D-dimer (indicating fibrin degradation), in plasma samples
other than in blister fluid (120, 121, 123). During the disease
remission, blood concentration of coagulation activationmarkers
returns to normal (49, 145). Moreover, the concentration of the
prothrombin fragment F1+2 correlates with the concentration
of immunoglobulins directed against the BP180 antigen (120).
All together, these findings clearly indicate that in BP patients
there may be an activation of coagulation also at systemic level.
A recent study has shown that plasma levels of prothrombotic
markers are higher in BP patients when compared with patients
affected with CSU (49). In pathological states, especially in
inflammatory disorders, the balance between the coagulation
and fibrinolysis might be deteriorated (152, 153). It is well
known that the inflammatory response inhibits fibrinolysis. The
results of a previous study on a group of patients with active
BP showed that fibrinolysis is inhibited, due mainly to an
increase in the plasma levels of plasminogen activator inhibitor
type 1 (PAI-1) activity and antigen (154). The most important
clinical consequence of the hypercoagulable state related to both
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coagulation activation and fibrinolysis inhibition in BP patients
is an increased thrombotic risk. It has been consistently reported
that the risk of thrombosis is increased in patients with BP
(155, 156) and we have found an annual incidence of venous
thrombosis of 8% (120), undoubtedly higher than that observed
in the general elderly population (157). Langan et al. investigated
the main acute medical conditions associated with BP, finding
an increased risk for pulmonary embolism (158). A recent
multicenter cohort study has shown that the risk of developing
venous thromboembolism (VTE) is increased 4-fold in patients
with BP as compared with the general population of same age
and sex (159). More specifically, the VTE risk increased up to
15 times during the acute phase of the disease, thus indicating
a close link between the inflammatory state occurring in active
BP and thrombosis. Interestingly, the VTE risk dropped to 1.5
times during clinical remission. This latter finding indicates that
a good control of the disease also impacts the occurrence of
thrombotic events. This study highlighted in a large cohort of
BP patients the close connection between the inflammatory state
and risk of VTE. This further emphasizes the tight interplay
between inflammation and coagulation cascade. In general, the
cardiovascular risk in BP patients may be influenced not only by
the inflammatory state but also by the treatment with systemic
corticosteroids and immunosuppressive agents (160).
The high thrombotic tendency found in patients with BP,
especially during the acute phase of the disease, implies some
practical considerations. Firstly, onemay wonder whether adding
VTE prophylaxis to the immunosuppressive treatments could
affect the thrombotic risk of BP patients. Clinical trials on
efficacy and safety of antithrombotic drugs administered in the
acute phase of the disease could provide some insight into their
clinical relevance.
CONCLUSIONS
Coagulation and fibrinolysis activation markers are elevated
in many inflammatory conditions, including not only a wide
spectrum of systemic diseases of different pathogenesis such as
rheumatoid arthritis, inflammatory bowel diseases, and sepsis
but also autoimmune or immune-mediated cutaneous disorders.
The activation of coagulation in autoimmune skin disorders may
have two main consequences: on one hand, a local pathogenic
role in inducing the skin lesions and on the other hand a
systemic role in increasing the thrombotic risk. Concerning
the pathophysiology of the skin lesions, thrombin contributes
to increase endothelial vascular permeability, thus amplifying
the inflammatory network in CU, angioedema and BP. In the
skin microenvironment of CU and BP, eosinophils express
tissue factor, which can activate coagulation right there, with
the generation of vascular permeability mediators. Concerning
the systemic implications of the coagulation involvement,
several data indicate an increased thrombotic risk in BP. In
contrast, no data are available concerning the incidence of
thrombotic complications in patients with CU and angioedema.
The retrospective evaluation of a large cohort of patients with
BP has shown an increased incidence of venous thrombosis.
Although most BP patients are elderly, the incidence of venous
thrombosis in this kind of patients appears to be significantly
increased as compared to the age-matched population of
otherwise healthy subjects. BP is the prototype of autoimmune
blistering disorder mediated by autoantibodies but in which
an important physiopathological role is played by eosinophils.
The intense skin inflammatory infiltrate is in fact characterized
by the presence of eosinophils together with autoreactive
CD4+ T lymphocytes and a few other inflammatory cells.
The increased incidence of thrombosis in autoimmune skin
diseases raises the question of the indication of anticoagulant
treatment particularly in the presence of other cardiovascular
risk factors.
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